



The Confounding Issue of Comorbid Renal Insufficiency

Gregg C. Fonarow, MD,^a and J. Thomas Heywood, MD^b

^aDivision of Cardiology, David Geffen School of Medicine at UCLA, University of California–Los Angeles, Los Angeles, California, USA; and ^bScripps Clinic, La Jolla, California, USA

ABSTRACT

The United States is currently beleaguered by twin epidemics, heart failure (HF) and renal insufficiency (RI). HF and RI frequently coexist in the same patient, and this conjunction, often called the “cardiorenal syndrome,” has important therapeutic and prognostic implications. Approximately 60% to 80% of patients hospitalized for HF have at least stage III renal dysfunction as defined by the National Kidney Foundation (NKF), and this comorbid RI is associated with significantly increased morbidity and mortality risk. Numerous studies have demonstrated that in patients with HF, indices of renal function are the most powerful independent mortality risk predictors. Comorbid RI can result from both intrinsic renal disease and inadequate renal perfusion. Atherosclerosis, renal vascular disease, diabetes mellitus, and hypertension are significant precursors of both HF and RI. Moreover, diminished renal perfusion is frequently a consequence of the hemodynamic changes associated with HF and its treatment. Both HF and RI stimulate neurohormonal activation, increasing both preload and afterload and reducing cardiac output. Inotropic agents augment this neurohormonal activation. In addition, diuretics can produce hypovolemia and intravenous vasodilators can cause hypotension, further diminishing renal perfusion. Management of these patients requires successfully negotiating the delicate balance between adequate volume reduction and worsening renal function. Despite this, few evidence-based data are available to guide management decisions, indicating a compelling need for additional studies in this patient population. © 2006 Elsevier Inc. All rights reserved.

KEYWORDS: Cardiorenal syndrome; Glomerular filtration rate; Heart failure; Outcomes; Renal insufficiency; Treatment

Twin epidemics, heart failure (HF) and renal insufficiency (RI) currently besiege the United States. It is not surprising that the prevalence of these twin syndromes continues to escalate, given an aging population, rising rates of obesity and diabetes mellitus, and shared risk factors. These issues have important implications for the healthcare system. Not uncommonly, HF and RI coexist in the same patient.^{1–3} This conjunction, often called the “cardiorenal syndrome,” has important therapeutic and prognostic implications for patients with HF. Much of the challenge of achieving successful HF management lies in navigating between the Scylla of fluid overload and the Charybdis of worsening renal function.

Requests for reprints should be addressed to Gregg C. Fonarow, MD, Division of Cardiology, David Geffen School of Medicine at UCLA, University of California–Los Angeles, 10833 Le Conte Avenue, Los Angeles, California 90095.

E-mail address: gfonarow@mednet.ucla.edu.

The cardiorenal syndrome is receiving significant attention from researchers, government agencies, and the pharmaceutical/device industry.⁴ In 2004, the National Heart, Lung, and Blood Institute (NHLBI) convened a working group to “evaluate the current state of knowledge regarding interactions between the cardiovascular system and the kidney, to identify critical gaps in our knowledge, understanding, and application of research tools, and to develop specific recommendations for NHLBI in cardio-renal interactions related to heart failure.”⁴ Although intense focus has been placed on the syndrome, a clear definition of cardiorenal syndrome has not yet been developed. Several definitions have been proposed, including the following:

- “A pathophysiologic condition in which combined cardiac and renal dysfunction amplifies progression of failure of the individual organ to lead to astounding morbidity and mortality in this patient group”⁵

- “Presence or development of renal dysfunction in patients with heart failure”⁶
- “A syndrome in which the heart or the kidney fails to compensate for the functional impairment of the respective other organ, resulting in a vicious cycle [*sic*] that will ultimately result in decompensation of the entire circulatory system”⁷
- “The result of interactions between the kidneys and other circulatory compartments that increase circulating volume and symptoms of heart failure and disease progression are exacerbated. At its extreme, cardio-renal dysregulation leads to what is termed ‘cardio-renal syndrome’ in which therapy to relieve congestive symptoms of heart failure is limited by further decline in renal function”⁴

EPIDEMIOLOGY OF HEART FAILURE WITH COMORBID RENAL INSUFFICIENCY

Data from several sources demonstrate that approximately 20% to 40% of patients admitted to a hospital for acute HF syndromes (AHFS) have comorbid RI, based on clinical history and serum creatinine levels. In an evaluation of data from 1,681 patients ≥ 65 years of age admitted for acute decompensated HF (ADHF) at 18 hospitals in Connecticut, 21% of patients had baseline renal failure and 41% had a baseline serum creatinine level ≥ 1.5 mg/dL (1 mg/dL = 76.25 $\mu\text{mol/L}$).⁸ Similarly, renal dysfunction complicated HF management in 18% of the 11,327 patients admitted to 115 hospitals in the EuroHeart Failure survey program.⁹ Finally, 30% of hospitalized patients with HF had a history of chronic RI and 20% had a serum creatinine level > 2 mg/dL in an evaluation of 105,388 hospitalization episodes at 274 hospitals from the Acute Decompensated Heart Failure National Registry (ADHERE).¹⁰

Moreover, these data probably underestimate the true prevalence of RI associated with HF. Patients with AHFS typically are elderly; the mean age of patients in the report from the ADHERE registry was 72.4 years.¹⁰ In the elderly, creatinine production is reduced owing to an age-related decline in muscle mass. As a result, serum creatinine concentration alone may not accurately reflect renal function.^{6,11} Currently, the National Kidney Foundation (NKF) recommends that renal function be assessed by estimating the glomerular filtration rate (GFR) based on predictive equations that take into account not only serum creatinine level but also other factors such as age, sex, race/ethnicity, and body size.¹¹ Based on estimated GFR, a majority of patients in the ADHERE registry have at least stage III renal dysfunction as defined by the NKF.^{11,12}

Additionally, comorbid RI can complicate the management of AHFS, even when it is not present at the time of admission. Between 27% and 45% of patients hospitalized for AHFS develop an acute worsening of renal function, defined as a ≥ 0.3 -mg/dL increase in serum creatinine level, during their hospitalization.^{8,13-15}




Figure 1 Proportional relation of glomerular filtration rate with mortality in a Cox-adjusted survival analysis of 1,702 patients with moderate-to-severe (i.e., New York Heart Association [NYHA] class III to IV) heart failure. (Adapted with permission from *Circulation*.¹⁶)

EFFECT OF RENAL INSUFFICIENCY ON PROGNOSIS

Several studies have demonstrated that patients with chronic HF who have developed RI have an increased risk of mortality. In the Second Prospective Randomized Study of Ibopamine on Mortality and Efficacy (PRIME-II), estimated baseline GFR was the most powerful multivariate predictor of mortality risk, exceeding both functional status and ejection fraction (**Figure 1**).¹⁶ Similarly, retrospective multivariate analysis of data from the Studies in Left Ventricular Dysfunction (SOLVD) prevention and treatment trials found that moderate RI, defined as a baseline creatinine clearance < 60 mL/min as estimated by the Cockcroft-Gault equation,¹⁷ was associated with a 1.41-fold increase ($P = 0.001$) in the risk of all-cause mortality in both trials.¹⁸

Baseline RI has also been shown to increase both morbidity and mortality risk in patients hospitalized for AHFS.¹⁹⁻²⁵ In a retrospective analysis of data from 1,129 patients, a discharge serum creatinine level > 2.5 mg/dL was the most powerful independent multivariate predictor of all-cause readmission (hazard ratio [HR], 1.72; 95% confidence interval [CI], 1.35 to 2.18; $P = 0.0001$).²⁴ In a multivariate Cox regression analysis of data from 541 patients, all-cause mortality increased with each quartile of blood (serum) urea nitrogen (BUN), with an adjusted mortality relative risk of 2.3 (95% CI, 1.3 to 4.1; $P = 0.005$) for patients in the highest compared with the lowest quartile.²¹ In separate multivariate analyses of data from 906 and 4,031 patients, a 5-mg/dL (1 mg/dL = 0.357 mmol/L) increase in BUN was associated with an increase in the 60-day risk of death or rehospitalization (odds ratio [OR], 1.28; 95% CI, 1.14 to 1.41; $P = 0.0001$) in the first analysis²² and a

Table 1 Etiologies of comorbid renal insufficiency in patients with heart failure

- Intrinsic renal disease
 - Renal vascular disease
 - Nephron loss (diabetes mellitus, hypertension)
 - Diuretic resistance
- Inadequate renal perfusion
 - Hypovolemia (inadequate preload)
 - Inadequate cardiac output (excessive vasoconstriction)
 - Hypotension
 - With normal cardiac output (vasodilatory shock)
 - With low cardiac output (severe pump failure, cardiogenic shock)
 - Abnormally high central venous pressure
 - Drug-induced (NSAIDs, cyclosporine, tacrolimus, ACE inhibitors, ARBs, etc)

ACE = angiotensin-converting enzyme; ARBs = angiotensin II receptor blockers; NSAIDs = nonsteroidal anti-inflammatory drugs.

Adapted from *Heart Fail Rev*.⁶

10-mg/dL increase in BUN was associated with an increased risk of both 30-day (OR, 1.55; 95% CI, 1.42 to 1.71; $P < 0.001$) and 1-year (OR, 1.49; 95% CI, 1.39 to 1.60; $P < 0.001$) mortality in the second analysis.²³ In an analysis of data from 433 patients in the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE), both baseline serum creatinine (HR, 1.37 per 0.2-mg/dL increase; 95% CI, 1.20 to 1.56; $P < 0.0001$) and BUN (HR, 1.42 per 20-mg/dL increase; 95% CI, 1.26 to 1.60; $P < 0.0001$) levels were significant independent 6-month mortality risk factors.¹⁹ Finally, in a classification and regression tree analysis of >33,000 ADHF hospitalization episodes in the ADHERE registry assessing >40 univariate predictors, admission serum creatinine and BUN levels were 2 of the 3 strongest independent risk predictors for inhospital mortality.²⁰

Similarly, worsening renal function during hospitalization for AHFS also signifies a significantly poorer prognosis.^{8,13–15} Gottlieb and colleagues¹⁴ evaluated data from 1,002 patients admitted to academic medical centers for ADHF. Approximately 72% of patients had a serum creatinine increase ≥ 0.1 mg/dL during their hospitalization, and even this small increase was associated with worse outcomes. Increasing the serum creatinine threshold used to define worsening renal function from ≥ 0.1 mg/dL to ≥ 0.5 mg/dL improved specificity but reduced sensitivity, with a level of ≥ 0.3 mg/dL providing both relatively high sensitivity (81%) and useful specificity (62%) for inhospital mortality. Smith and colleagues¹³ evaluated the mortality risk associated with acute serum creatinine elevation in 412 patients hospitalized for ADHF. Adjusted 6-month mortality HRs were 0.88 (95% CI, 0.49 to 1.57) for a ≥ 0.1 -mg/dL increase, 1.15 (95% CI, 0.67 to 1.97) for a ≥ 0.2 -mg/dL increase, 1.61 (95% CI, 0.94 to 2.77) for a ≥ 0.3 -mg/dL increase, 1.83 (95% CI, 1.05 to 3.23) for a ≥ 0.4 -mg/dL increase, and 2.86 (95% CI, 1.55 to 5.26) for a ≥ 0.5 -mg/dL increase in serum creatinine. A $\geq 25\%$ increase in serum creatinine had high specificity (91%) but lacked sensitivity (14%) and was not statistically significant (adjusted

6-month mortality HR, 1.67; 95% CI, 0.78 to 3.56). In summary, a significant component of the morbidity and mortality associated with HF is predicted by RI.

PATHOPHYSIOLOGIC LINK BETWEEN HEART FAILURE AND RENAL INSUFFICIENCY

In patients with HF, comorbid RI can result from intrinsic renal disease, hemodynamic abnormalities, or their combination (**Table 1**).⁶ Atherosclerosis, renal vascular disease, diabetes, and hypertension are significant precursors of both renal dysfunction and HF.^{1,11,26,27} As a result, intrinsic renal disease frequently coexists with HF.²⁸

Diminished renal perfusion is frequently a consequence of the hemodynamic changes associated with HF and its treatment. Severe pump failure leads to low cardiac output and hypotension (cardiogenic shock).²⁹ Neurohormonal activation produces both fluid retention, increasing central venous pressure, and vasoconstriction, increasing afterload and diminishing cardiac output.^{29,30} Diuresis can cause hypovolemia, reducing preload,⁶ and use of intravenous vasodilators can lead to hypotension.^{31,32} In addition, agents such as nonsteroidal anti-inflammatory drugs (NSAIDs), cyclosporine, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARBs) all can decrease renal perfusion.^{33–36} The resultant diminution in renal blood flow/GFR can lead to RI even in the absence of intrinsic renal disease.

In patients with HF, there is a correlation between RI and circulating levels of neurohormones. Activation of the renin-angiotensin-aldosterone system (RAAS) leads to renal hypoxia, vasoconstriction, intraglomerular hypertension, glomerulosclerosis, tubulointerstitial fibrosis, and proteinuria.^{26,37,38} Similarly, sympathetic nervous system activation causes proliferation of smooth muscle cells and adventitial fibroblasts in the vascular wall of intrarenal blood vessels.³⁹

High central venous pressure is another cause of renal dysfunction that is often overlooked. In an elegant study,

Firth and colleagues⁴⁰ evaluated the effect of increasing venous pressure on GFR using an isolated rat kidney preparation. Normal perfusion pressure was maintained while venous pressure was increased in 6.25-mm Hg steps. In this evaluation, increasing venous pressure above 19 cm of water produced significant reductions in GFR, sodium excretion, and fractional excretion of sodium, which resolved completely when venous pressure was restored to basal levels. Angiotensin II–induced vasoconstriction of the efferent glomerular arteriole helps to preserve GFR in patients with HF and RI.^{41,42} Neurohormonal blockade with ACE inhibitors and/or ARBs impedes this vasoconstriction, reducing glomerular capillary pressure and, hence, GFR, leading to an acute, small increase in serum creatinine level.^{33,35,43} Although initially worrisome, especially given the mortality risk associated with similar acute increases in serum creatinine level in patients with HF,^{8,13–15} the resultant decrease in glomerular hyperfiltration seems to be renoprotective over the long term, and supports continuation of these therapies in the absence of renal artery stenosis.^{33,44–47} Because patients who are volume-depleted may be especially sensitive to this efferent arteriolar vasodilation,^{45,47,48} restoring and maintaining a normal volume status before and throughout therapy with a neurohormonal blocking agent may help alleviate the initial acute decline in renal function.

In addition to the adverse effects of HF on renal function, RI adversely affects cardiac function, producing a vicious circle in which RI impairs cardiac performance, which then leads to further impairment of renal function. As a result, RI is a major determinant of the progression of HF, congestion, and recurrent decompensation and hospitalization.^{18,24,49} Neurohormonal activation is a key component that links not only RI to HF but also HF to RI (**Figure 2**).⁵⁰ Both HF and RI produce neurohormonal activation.^{39,50–52} This activation increases the volume and pressure load on the heart, reduces myocardial oxygen supply, promotes deleterious myocardial remodeling, and accelerates atherosclerosis.^{30,39}

The etiology of RI in patients with HF is complex, and several factors may be at work in the same patient. Given the increased morbidity and mortality associated with comorbid RI, recognizing which factors are involved in an individual patient and eliminating these factors whenever possible is an essential component of HF management.

THERAPEUTIC IMPLICATIONS

HF with comorbid RI can be difficult to manage because both cardiac and renal function are exquisitely dependent on circulating volume.²⁶ In these patients, the overall goals of management should be (1) to normalize volume status while avoiding overdiuresis and attendant renal dysfunction and (2) to implement evidence-based pharmacologic and device therapy to improve patient outcomes.⁷

An initial consideration is the identification of potentially reversible factors that may be contributing to cardiorenal dysfunction. In this regard, it is important to evaluate fluid

status, cardiac output, and evidence of intrinsic renal disease. The first question that should be answered in the patient with HF and RI is whether the patient is hypovolemic. Diuretics are an integral part of HF therapy. However, their overaggressive use or their use in combination with other factors, such as an intercurrent illness, frequently leads to hypovolemia, reducing both cardiac output and GFR.^{53,54} This hypovolemia should be reversed with fluid before irreversible renal damage ensues. A careful physical examination and limited echocardiogram with estimation of right and left atrial pressures will usually resolve this question, although invasive assessment of filling pressures will occasionally be necessary.⁶

The next item to consider is the adequacy of renal perfusion. Renal perfusion depends on both blood pressure and cardiac output. If hypotension is present, pressors should be used to maintain a systolic blood pressure >80 mm Hg and a mean blood pressure >60 mm Hg.^{2,31,55} If hypotension is not present, then cardiac output should be evaluated. In the absence of hypotension, cold extremities are frequently an indication of excessive vasoconstriction leading to low cardiac output and elevated systemic vascular resistance. These patients often respond favorably to vasodilation.⁵⁶ Renal function may improve as cardiac output and, hence, renal perfusion increase, and low-normal systolic blood pressure (80 to 90 mm Hg) should be tolerated as long as renal function is improving.⁶

Intrinsic renal disease should be suspected if RI persists after abnormalities in volume status, cardiac output, and systemic vascular resistance have been corrected. Typically, this is owing to nephron loss secondary to diabetes, hypertension, or renovascular disease.^{30,57,58} The presence of proteinuria usually indicates intrinsic renal disease and is associated with an increased risk for the development of chronic, progressive RI.⁵⁹ Depending on the degree of renal impairment, these patients may benefit from ultrafiltration or hemodialysis.^{6,60}

Lastly, the feasibility of discontinuing drugs that contribute to RI, such as aspirin and other NSAIDs, should be considered. ACE inhibitors and ARBs should be discontinued in patients with renovascular disease who develop a significant increase in their serum creatinine level, and these agents may need to be temporarily reduced or discontinued in patients who have excessive vasodilation.^{6,33} However, given their long-term beneficial effects in both HF and RI, therapy with an ACE inhibitor or ARB should be continued or reinstated whenever possible.^{1,3,47,59}

Diuretics

Treating AHFS with comorbid RI often requires the use of diuretics, inotropes, and/or vasodilators. Volume overload is a frequent component of both HF and RI and a major cause of clinical symptomatology. Consequently, diuretics play an important role in the treatment of both conditions.^{1,2,47} Their symptomatic benefit in patients with HF has led to almost universal clinical acceptance, even though




Figure 2 Pathophysiologic link between cardiac and renal failure. ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; BP = blood pressure; BUN = blood (serum) urea nitrogen; CAD = coronary artery disease; CO = cardiac output; CVP = central venous pressure; DM = diabetes mellitus; GFR = glomerular filtration rate; HF = heart failure; HTN = hypertension; LV = left ventricular; LVEF = LV ejection fraction; LVH = LV hypertrophy; Na⁺ = sodium; NSAIDs = nonsteroidal anti-inflammatory drugs; SCr = serum creatinine; SVR = systemic vascular resistance.

their efficacy and safety have never been evaluated in large-scale, randomized clinical trials.²

Both HF and RI influence the dose-response curve for diuretics. RI shifts the curve to the right, while HF shifts the curve both downward and to the right.⁶¹ This not only increases the dose required to produce a diuretic response but also decreases the maximum response that can be achieved, creating a state of relative diuretic resistance. Moreover, this increasing dose requirement and diminished responsiveness increases as HF progresses.⁶² It is also important to remember that diuretics have an S-shaped dose-response curve.⁶³ Consequently, for any individual patient there is a maximum dose above which nothing is gained by using larger doses.⁶³ Although HF and RI frequently require increasing doses of diuretics, it is essential to carefully assess the therapeutic response to these increases to make sure that one remains on the steep part of the dose-response curve.

Use of diuretics involves a delicate balance. The dose must be sufficient to achieve effective relief of fluid overload and its ensuing symptoms without stimulating adverse physiologic effects. Excessive diuresis produces hypovolemia and extracellular fluid contraction, leading to hypotension, reduced cardiac output, diminished GFR, and further impairment of renal function.^{2,47,53,64} Furthermore, this impairment in renal function has been correlated directly with the reduction in mean arterial blood pressure.⁶⁴ In addition, this extracellular fluid contraction increases the adverse renal effects of therapeutic agents used in the treatment of

HF, including ACE inhibitors, ARBs, and natriuretic peptides,^{33,45,47,65,66} as well as enhancing the risk of radiocontrast agents.⁶⁷

Diuretics also stimulate adverse neurohormonal activation.^{61,68–70} All diuretics induce extracellular volume contraction, which stimulates the secretion of renin while inhibiting the secretion of counterregulatory natriuretic peptides.⁶¹ In addition, loop diuretics augment renin secretion through 2 volume-independent mechanisms. They inhibit sodium chloride uptake into the macula densa cells, a central component of the macula densa-mediated pathway for renin secretion, and they stimulate the renal production of prostacyclin, further enhancing the secretion of renin.⁶¹ Data from the SOLVD trial demonstrate that diuretics can induce adverse neurohormonal activation in patients in whom it was not present before diuretic administration.⁶⁹

Finally, diuretics, especially high-dose diuretics, have been shown to increase mortality risk in patients with HF and/or RI.^{62,67,71} In the SOLVD trial, there was a significant increase in the risk of hospitalization or death due to worsening HF in patients receiving non-potassium-sparing diuretics compared with those not receiving diuretics (risk ratio, 1.31; 95% CI, 1.09 to 1.57; *P* = 0.0004).⁷¹ In the Prospective Randomized Amlodipine Survival Evaluation (PRAISE), use of high-dose diuretics was associated with increased total mortality (HR, 1.37; *P* = 0.004), sudden death (HR, 1.39; *P* = 0.042), and pump failure death (HR, 1.51; *P* = 0.034).⁶² However, the direct effect of diuretics on long-term HF outcomes cannot be established and must

Table 2 Risk of serum creatinine increase in patients receiving vasodilator: the Vasodilation in the Management of Acute Congestive HF (VMAC) analysis

Diuretic Dose Category	SCr Increase >0.5 mg/dL,* n (%)		NES/NTG RR (95% CI)	P value
	NES	NTG		
Low to moderate dose	24/119 (20.2)	17/81 (21.0)	0.96 (0.55–1.66)	0.975
High dose	49/149 (32.9)	28/131 (21.4)	1.50 (1.00–2.25)	0.044

NES = nesiritide; NTG = nitroglycerin; RR = relative risk; SCr = serum creatinine.

*1 mg/dL = 76.25 μ mol/L.

Adapted from *J Card Fail*.⁶⁶

be determined prospectively. Several studies suggest that a continuous infusion of diuretics is more effective than are intermittent boluses.^{72–79} When diuretic resistance persists, ultrafiltration should be considered. In patients with moderate-to-severe HF, ultrafiltration has been shown to improve symptoms, hemodynamics, urine output, and diuretic responsiveness.^{60,80–82} Moreover, unlike loop diuretics, ultrafiltration produces less long-term neurohormonal activation.^{80,81,83}

Inotropes

Inotropes augment contractility and are an essential component of the treatment of low-output HF manifested by cardiogenic shock. Their role in the treatment of other forms of HF, however, is less clearly established. Inotropes primarily target a physiologic parameter (cardiac output) that has not been associated with either improved symptoms or outcomes.^{31,84} They improve short-term hemodynamics but increase the risk of adverse events and mortality.^{84–88} Patients hospitalized for ADHF who received milrinone or dobutamine had significantly increased inhospital mortality compared with those who received nitroglycerin or nesiritide after adjusting for differences in baseline covariates and propensity score in an analysis of data from the ADHERE registry.⁸⁵ In the ESCAPE trial, after adjustment for renal function and blood pressure, use of inotropic agents was associated with significant increases in the risk of death (HR, 1.75; 95% CI, 1.05 to 2.92; $P = 0.032$) and death plus rehospitalization (HR, 2.12; 95% CI, 1.52 to 2.97; $P < 0.001$).⁸⁷ These adverse effects may, in part, be due to augmentation of the deleterious neurohormonal activation that is already present in patients with AHFS. In a multicenter evaluation of patients with stable HF, treatment with levosimendan or dobutamine was associated with a significant, 23% to 43% increase in plasma renin levels compared with baseline ($P \leq 0.007$),⁸⁹ and in a multicenter evaluation of patients admitted for ADHF, dobutamine treatment was associated with a significant, 31% increase in plasma aldosterone levels ($P < 0.001$).⁹⁰ In selected patients with refractory low output syndrome and RI, expeditious placement of a left ventricular assist device may restore clinical stability and reversal of renal dysfunction.⁹¹

Vasodilators

Vasodilators decrease preload and afterload, reducing ventricular work, increasing stroke volume, and augmenting cardiac output.⁸⁴ They are indicated in patients with AHFS who have signs of congestion and hypoperfusion with adequate blood pressure.²

Nitrates effectively relieve pulmonary congestion, and their use, in combination with a low-dose diuretic, has proved to be more efficacious than high-dose diuretic therapy alone in patients with AHFS.² Nitrate dosing must be carefully titrated to produce optimal vasodilation because excessive or inappropriate vasodilation causes a rapid decline in blood pressure with resultant reflexive sympathetic activation and tachycardia, RAAS activation, and fluid retention.^{2,92,93} In addition, tolerance to nitrates develops quickly, especially when they are given intravenously in high doses, generally limiting the duration of effectiveness to 24 to 48 hours and necessitating central hemodynamic monitoring in an intensive care unit setting.^{2,93}

Human B-type natriuretic peptide (hBNP) is a counter-regulatory hormone produced by the ventricles in response to pressure and volume load.^{2,51} In patients with HF, hBNP produces balanced vasodilation, improves cardiac output, and inhibits activity of the RAAS, sympathetic nervous system, and endothelin system.^{2,94–98} Renal effects are variable and may depend on underlying volume status and renal function. In patients with HF, hBNP has been reported to either decrease⁹⁹ or maintain renal blood flow and/or GFR^{94,97,98,100,101} and to either maintain^{94,101} or increase urinary sodium and/or water excretion.^{96–98}

Nesiritide is a recombinant form of hBNP. In a small evaluation of 13 patients with HF who underwent cardiac catheterization, nesiritide exerted a renal vasodilatory effect, which maintained renal blood flow despite a significant decrease in renal perfusion pressure.¹⁰⁰ In a meta-analysis including suprathreshold doses of nesiritide, risk of acute serum creatinine elevation paralleled the prevalence of symptomatic hypotension¹⁰²; in an analysis of data from the Vasodilation in the Management of Acute Congestive HF (VMAC) trial, the risk of acute serum creatinine elevation was significantly increased in patients treated with nesiritide who received high-dose diuretics (Table 2).⁶⁶ It is not yet clear whether the observed increase in creatinine is associ-

ated with adverse outcomes. In a pooled analysis of 5 randomized nesiritide trials, increases in serum creatinine (>0.5 mg/dL) that occurred in patients treated with nesiritide were not associated with an increased risk of mortality at 30 days.¹⁰³

SUMMARY

Patients admitted to a hospital for AHFS frequently have comorbid RI, and this insufficiency significantly influences both treatments and outcomes. Compared with patients with HF who have normal renal function, patients with comorbid RI have significantly increased morbidity and mortality, but evidence-based data to guide management decisions in these patients are lacking. There is a compelling need for additional studies in this population to create alternative methods for fluid removal in volume-overloaded patients; to develop better strategies to manage existing and prevent future RI, including the development of renal-protective medications; and to reduce the morbidity and mortality associated with AHFS and comorbid RI.

References

- Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). [published correction appears in *J Am Coll Cardiol*. 2006;47:1503–1505]. *J Am Coll Cardiol* 2005;46:e1–e82.
- Nieminen MS, Böhm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. *Eur Heart J*. 2005;26:384–416.
- Swedberg K, Cleland J, Dargie H, et al, for the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). *Eur Heart J*. 2005;26:1115–1140.
- NHLBI Working Group. Cardio-renal connections in heart failure and cardiovascular disease: executive summary. Available at: <http://www.nhlbi.nih.gov/meetings/workshops/cardiorenal-hf-hd.htm>. Accessed June 20, 2006.
- Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: Guyton revisited. *Eur Heart J*. 2005; 26:11–17.
- Heywood JT. The cardiorenal syndrome: lessons from the ADHERE database and treatment options. *Heart Fail Rev*. 2004;9:195–201.
- Boerrigter G, Burnett JC Jr. Cardiorenal syndrome in decompensated heart failure: prognostic and therapeutic implications. *Curr Heart Fail Rep*. 2004;1:113–120.
- Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients ≥ 65 years of age with heart failure. *Am J Cardiol*. 2000;85:1110–1113.
- Cleland JGF, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. *Eur Heart J*. 2003;24:442–463.
- Adams KF Jr, Fonarow GC, Emerman CL, et al, for the ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Failure National Registry (ADHERE). *Am Heart J*. 2005;149:209–216.
- Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Ann Intern Med*. 2003;139:137–147.
- Heywood JT, Fonarow GC, Wynne J. Is heart failure really renal failure? Observations from 88,075 admissions with decompensated heart failure in the ADHERE Registry. *J Am Coll Cardiol*. 2005; 45(suppl A):173A. Abstract 843-8.
- Smith GL, Vaccarino V, Kosiborod M, et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? *J Card Fail*. 2003;9:13–25.
- Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. *J Card Fail*. 2002;8:136–141.
- Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. *J Am Coll Cardiol*. 2004;43:61–67.
- Hillege HL, Girbes ARJ, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. *Circulation*. 2000;102:203–210.
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron*. 1976;16:31–41.
- Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. *J Am Coll Cardiol*. 2000;35:681–689.
- Hill JA, Shah MR, Hasselblad V, et al. Pulmonary artery catheter use does not change the contribution of renal dysfunction to outcomes in patients with advanced heart failure: findings from ESCAPE. *Circulation*. 2004;110(suppl 3):III-638. Abstract 2964.
- Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ, for the ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. *JAMA*. 2005;293:572–580.
- Aronson D, Mittleman MA, Burger AJ. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. *Am J Med*. 2004;116:466–473.
- Felker GM, Gattis WA, Leimberger JD, et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. *Am J Cardiol*. 2003;92:625–628.
- Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. *JAMA*. 2003;290:2581–2587.
- Krumholz HM, Chen Y-T, Wang Y, Vaccarino V, Radford MJ, Horwitz RI. Predictors of readmission among elderly survivors of admission with heart failure. *Am Heart J*. 2000;139:72–77.
- Jong P, Vowinkel E, Liu PP, Gong Y, Tu JV. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. *Arch Intern Med*. 2002;162:1689–1694.
- McCullough PA, Kuncheria J, Mathur VS. Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. *Rev Cardiovasc Med*. 2004; 5:16–25.
- Gray BH, Olin JW, Childs MB, Sullivan TM, Bacharach JM. Clinical benefit of renal artery angioplasty with stenting for the control of recurrent and refractory congestive heart failure. *Vasc Med*. 2002;7: 275–279.
- Collins AJ. Cardiovascular mortality in end-stage renal disease. *Am J Med Sci*. 2003;325:163–167.
- Cotter G, Moshkovitz Y, Milovanov O, et al. Acute heart failure: a novel approach to its pathogenesis and treatment. *Eur J Heart Fail*. 2002;4:227–234.
- Brewster UC, Setaro JF, Perazella MA. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. *Am J Med Sci*. 2003;326:15–24.

31. Fonarow GC. Pharmacologic therapies for acutely decompensated heart failure. *Rev Cardiovasc Med.* 2002;3(suppl 4):S18–S27.
32. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. *JAMA.* 2002;287:1531–1540.
33. Epstein BJ. Elevations in serum creatinine concentration: concerning or reassuring? *Pharmacotherapy.* 2004;24:697–702.
34. Juhlin T, Björkman S, Gunnarsson B, Fyge Å, Roth B, Höglund P. Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors. *Eur J Heart Fail.* 2004;6:909–916.
35. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. *Circulation.* 2001;104:1985–1991.
36. Sanchez V, Delgado JF, Morales JM, et al. Chronic cyclosporine-induced nephrotoxicity in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine. *Transplant Proc.* 2004;36:2823–2825.
37. Silverberg D, Wexler D, Blum M, Schwartz D, Iaina A. The association between congestive heart failure and chronic renal disease. *Curr Opin Nephrol Hypertens.* 2004;13:163–170.
38. Yoshida H, Yashiro M, Liang P, et al. Mesangiolytic glomerulopathy in severe congestive heart failure. *Kidney Int.* 1998;53:880–891.
39. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. *Hypertension.* 2004;43:699–706.
40. Firth JD, Raine AE, Ledingham JG. Raised venous pressure: a direct cause of renal sodium retention in oedema? *Lancet.* 1988;1:1033–1035.
41. Ichikawa I, Pfeffer JM, Pfeffer MA, Hostetter TH, Brenner BM. Role of angiotensin II in the altered renal function of congestive heart failure. *Circ Res.* 1984;55:669–675.
42. Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. *Drugs.* 1990;39(suppl 4):10–21.
43. Packer M. Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. *Am J Cardiol.* 1987;60:179–184.
44. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. *Kidney Int.* 1998;54:1283–1289.
45. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? *Arch Intern Med.* 2000;160:685–693.
46. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. *N Engl J Med.* 1993;329:1456–1462.
47. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis.* 2004;43(suppl 1):S1–S290.
48. Ljungman S, Kjekshus J, Swedberg K, for the CONSENSUS Trial Group. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). *Am J Cardiol.* 1992;70:479–487.
49. Akhter MW, Aronson D, Bitar F, et al. Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. *Am J Cardiol.* 2004;94:957–960.
50. Bongartz LG, Cramer MJ, Braam B. The cardiorenal connection [letter]. *Hypertension.* 2004;43:e14.
51. Boerrigter G, Burnett JC Jr. Recent advances in natriuretic peptides in congestive heart failure. *Expert Opin Investig Drugs.* 2004;13:643–652.
52. Yeyati NL, Adrogué HJ. Inappropriately high plasma renin activity accompanies chronic loss of renal function. *Am J Nephrol.* 1996;16:471–477.
53. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A₁ adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. *Circulation.* 2002;105:1348–1353.
54. Ikram H, Chan W, Espiner EA, Nicholls MG. Haemodynamic and hormone responses to acute and chronic furosemide therapy in congestive heart failure. *Clin Sci.* 1980;59:443–449.
55. Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: inotropic infusions during hospitalization. *Circulation.* 2003;108:367–372.
56. Chatterjee K, Parmley WW, Cohn JN, et al. A cooperative multi-center study of captopril in congestive heart failure: hemodynamic effects and long-term response. *Am Heart J.* 1985;110:439–447.
57. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. *Hypertension.* 2004;44:595–601.
58. Caps MT, Perissinotto C, Zierler RE, et al. Prospective study of atherosclerotic disease progression in the renal artery. *Circulation.* 1998;98:2866–2872.
59. Keane WF. Proteinuria: its clinical importance and role in progressive renal disease. *Am J Kidney Dis.* 2000;35:S97–S105.
60. Marenzi G, Lauri G, Grazi M, Assanelli E, Campodonico J, Agostoni P. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. *J Am Coll Cardiol.* 2001;38:963–968.
61. Ellison DH. Diuretic therapy and resistance in congestive heart failure. *Cardiology.* 2001;96:132–143.
62. Neuberger GW, Miller AB, O'Connor CM, et al, for the PRAISE Investigators. Diuretic resistance predicts mortality in patients with advanced heart failure. *Am Heart J.* 2002;144:31–38.
63. Brater DC. Diuretic therapy. *N Engl J Med.* 1998;339:387–395.
64. Cotter G, Weissgarten J, Metzko E, et al. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. *Clin Pharmacol Ther.* 1997;62:187–193.
65. Palmer BF. Impaired renal autoregulation: implications for the genesis of hypertension and hypertension-induced renal injury. *Am J Med Sci.* 2001;321:388–400.
66. Heywood JT. Combining nesiritide with high-dose diuretics may increase the risk of increased serum creatinine. *J Card Fail.* 2005;11(suppl):S154. Abstract 950473.
67. Mehta RL, Pascual MT, Soroko S, Chertow GM, for the PICARD Study Group. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. *JAMA.* 2002;288:2547–2553.
68. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis. *Ann Intern Med.* 1985;103:1–6.
69. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). *Circulation.* 1990;82:1724–1729.
70. Kubo SH, Clark M, Laragh JH, Borer JS, Cody RJ. Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics. *Am J Cardiol.* 1987;60:1322–1328.
71. Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). *J Am Coll Cardiol.* 2003;42:705–708.
72. Dormans TPJ, van Meyel JJM, Gerlag PGG, Tan Y, Russel FGM, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. *J Am Coll Cardiol.* 1996;28:376–382.

73. Kramer WG, Smith WB, Ferguson J, et al. Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure. *J Clin Pharmacol*. 1996;36:265–270.
74. Lahav M, Regev A, Ra'anani P, Theodor E. Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. *Chest*. 1992;102:725–731.
75. McBride BF, White CM. Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic management. *Pharmacotherapy*. 2003;23:997–1020.
76. Pivac N, Rumboldt Z, Sardelic S, et al. Diuretic effects of furosemide infusion versus bolus injection in congestive heart failure. *Int J Clin Pharmacol Res*. 1998;18:121–128.
77. Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. *Cochrane Database Syst Rev*. 2004;(1):CD003178.
78. Schuller D, Lynch JP, Fine D. Protocol-guided diuretic management: comparison of furosemide by continuous infusion and intermittent bolus. *Crit Care Med*. 1997;25:1969–1975.
79. van Meyel JJ, Smits P, Dormans T, Gerlag PG, Gribnau FW. Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance. *J Intern Med*. 1994;235:329–334.
80. Agostoni P, Marenzi G, Lauri G, et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. *Am J Med*. 1994;96:191–199.
81. Agostoni PG, Marenzi GC, Pepi M, et al. Isolated ultrafiltration in moderate congestive heart failure. *J Am Coll Cardiol*. 1993;21:424–431.
82. Kiyngi A, Field MJ, Pawsey CC, Yiannikas J, Lawrence JR, Arter WJ. Metolazone in treatment of severe refractory congestive cardiac failure. *Lancet*. 1990;335:29–31.
83. Ellison DH. Diuretic resistance: physiology and therapeutics. *Semin Nephrol*. 1999;19:581–597.
84. DiDomenico RJ, Park HY, Southworth MR, et al. Guidelines for acute decompensated heart failure treatment. *Ann Pharmacother*. 2004;38:649–660.
85. Abraham WT, Adams KF, Fonarow GC, et al, for the ADHERE Scientific Advisory Committee and Investigators and the ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure treated with intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). *J Am Coll Cardiol*. 2005;46:57–64.
86. Arnold LM, Carroll NV, Oinonen M, Crouch MA. Mortality and length of hospital stay in patients receiving dobutamine, milrinone, or nesiritide for acute decompensated heart failure. *J Card Fail*. 2004;10(suppl 4):S103. Abstract 317.
87. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy during heart failure hospitalization in the ESCAPE Trial. *Circulation*. 2004;110(suppl 3):III-515. Abstract 2415.
88. Ewy GA. Inotropic infusions for chronic congestive heart failure: medical miracles or misguided medicinals? *J Am Coll Cardiol*. 1999;33:572–575.
89. Nieminen MS, Akkila J, Hasenfuss G, et al, on behalf of the Study Group. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. *J Am Coll Cardiol*. 2000;36:1903–1912.
90. Aronson D, Horton DP, Burger AJ. The effect of dobutamine on neurohormonal and cytokine profiles in patients with decompensated congestive heart failure. *J Card Fail*. 2001;7(suppl 2):28. Abstract 095.
91. de Vivo F, DeSanto LS, Maiello C, et al. Role of the heart surgeon in the emergency treatment of diuretic resistant edema in grades III-IV heart failure. *Kidney Int Suppl*. 1997;59:S66–S68.
92. Ferreira A, Bettencourt P, Dias P, et al. Neurohormonal activation, the renal dopaminergic system and sodium handling in patients with severe heart failure under vasodilator therapy. *Clin Sci*. 2001;100:557–566.
93. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. *N Engl J Med*. 1987;317:799–804.
94. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. *J Card Fail*. 1998;4:37–44.
95. Aronson D, Burger AJ. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. *Am J Cardiol*. 2002;90:435–438.
96. Colucci WS, Elkayam U, Horton DP, et al, for the Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. *N Engl J Med*. 2000;343:246–253.
97. Jensen KT, Eiskjaer H, Carstens J, Pedersen EB. Renal effects of brain natriuretic peptide in patients with congestive heart failure. *Clin Sci (Lond)*. 1999;96:5–15.
98. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind, placebo-controlled, randomized crossover trial. *Circulation*. 1996;94:3184–3189.
99. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. *Circulation*. 2005;111:1487–1491.
100. Elkayam U, Singh H, Akhter MW, et al. Effects of intravenous nesiritide on renal hemodynamics in patients with congestive heart failure. *J Card Fail*. 2004;10(suppl 4):S88. Abstract 256.
101. Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. *Circulation*. 2004;110:1620–1625.
102. Abraham WT. Serum creatinine elevations in patients receiving nesiritide are related to starting dose. *J Card Fail*. 2005;11(suppl):S156. Abstract 248.
103. Elkayam U. Nesiritide may diminish the increased acute mortality risk associated with worsening renal function. *Circulation*. 2005;112(suppl II):676. Abstract 3168.